Why the study?
Cancer therapies cause diverse cardiac toxicities, and strategies to address cardiovascular risk before, during, and after treatment are needed.
Emphasizes CV risk management throughout cancer therapy; leaves open optimal strategies for biomarker- or imaging-based stratification.
Cancer therapies can cause a variety of cardiac toxicities, including ischemia, cardiomyopathy, heart failure, myocarditis, arrhythmias, vascular disease, hypertension, and hyperlipidemia. Addressing cardiovascular risk at baseline, before initiating therapy, during cancer treatment, and in the survivorship period is imperative. It may be useful to risk stratify individuals with cardiovascular risk factors using biomarkers or imaging before they receive potentially cardiotoxic therapies. Additionally, new guidelines recommend cardiac imaging with echocardiography in the survivorship period 6 to 12 months after completing cancer therapy for these high-risk individuals. Close collaboration between cardiology and oncology in both clinical practice and future research is essential.
No takes yet. Share an insight, caveat, or question.
Blaes et al. (2018) conducted a review in Cardiac toxicities from cancer therapies. Cancer therapies was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: